- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03903588
The Heidelberg Engineering SPECTRALIS Macular Precision and Agreement Study
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New York
-
New York, New York, Estados Unidos, 10036
- State University of New York Optometry School
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion All Eye Populations
- Age 22 years or older
- Able and willing to undergo the test procedures, sign informed consent, and follow instructions
- Able to fixate
- Refraction between +6 and -6 diopters and astigmatism ≤ 2 diopters.
- Axial length ≤ 26.0 mm
Exclusion All Eye Populations
- Subjects unable to read or write
- Ocular media is not sufficiently clear to obtain acceptable quality images
- Physical inability to be properly positioned at the study devices or eye exam equipment
Inclusion Normal Population
- Eyes without prior intraocular surgery bilaterally (except cataract surgery and LASIK)
- Intraocular pressure ≤ 21mmHg
- Best corrected visual acuity ≥ 20/40
- Clinically normal appearance of the optic disc, with normal appearing neuroretinal rim with respect to color and shape, and clinically normal appearing posterior pole
- Both eyes must be determined to be normal, as determined by an investigator
Exclusion Normal Population
- Subjects with vitreal, retinal or choroidal conditions or disease of the optic nerve. Subjects may have diabetes but cannot have diabetic retinopathy.
- History of glaucoma (not including family history)
- Unreliable visual field as determined by the manufacturer's recommendations of:
Fixation losses > 20%, False Positives > 33%, False Negatives > 15%
-Visual field defects consistent with glaucomatous optic nerve damage based on at least one of the following two findings: On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level; Glaucoma hemi-field test "outside normal limits"
Inclusion Glaucoma Population
- Subjects who have a glaucoma diagnosis without prior non-glaucoma related intra-ocular surgery (except cataract surgery and LASIK)
- Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities:
Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles with or without disc hemorrhage; Localized abnormalities of the peripapillary retinal nerve fiber layer, especially at the inferior or superior poles; or Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue
- Visual field defects consistent with glaucomatous optic nerve damage based on at least one of the following two findings:
- On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level; Glaucoma hemi-field test "outside normal limits."
- Best corrected visual acuity ≥ 20/40
Exclusion Glaucoma Population
- Subjects with presence of any ocular pathology other than Glaucoma in the study eye (cataracts are acceptable)
- Unreliable visual field as determined by the manufacturer's recommendations of:
Fixation losses > 20%, False Positives > 33%, False Negatives > 15%
Inclusion Retina Population
- Subjects who have a retinal condition diagnosis without prior non-retinal related intra-ocular surgery (except cataract surgery and LASIK).
- Intraocular pressure ≤21mmHg
- Best corrected visual acuity ≥20/400
Exclusion Retina Population
-Subjects with presence of any ocular pathology other than retinal conditions in the study eye (cataracts are acceptable)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Normal
Eyes judged as age-appropriate normal as determined by an Investigator and that meet applicable inclusion/exclusion criteria.
|
Imaging of the Retina
Otros nombres:
|
|
Glaucoma
Eyes that have been diagnoses with Glaucoma
|
Imaging of the Retina
Otros nombres:
|
|
Retinal Disease
Eyes that have been diagnoses with a Retinal Disease
|
Imaging of the Retina
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Retinal Layer Thickness
Periodo de tiempo: 5 months
|
Measurement of the thickness of Retinal layers thickness to assess 2 grids
|
5 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- S-2018-2
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .